Ocugen Inc Stock Price, News & Analysis

Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, CEO and Co-Founder, will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022. A video webcast of the presentation will be available on demand starting at 7:00 a.m. ET for registered attendees and will be accessible on Ocugen's investor site for 90 days post-event. Ocugen focuses on developing innovative gene therapies, biologicals, and vaccines, particularly in retinal diseases and public health challenges.

Ocugen reported Q2 2022 financial results, highlighting significant milestones in its clinical programs. The Phase 2/3 COVAXIN™ trial is progressing, with positive data published supporting its use in children. The company's OCU400 gene therapy trial has completed dosing for Cohort 1, with plans to advance to Cohort 2. Ocugen introduced NeoCart®, a Phase 3-ready cell therapy, and received FDA's Regenerative Medicine Advanced Therapy designation. Financially, the company holds $115 million in cash, projecting operational funding into Q2 2023, despite a net loss of $0.09 per share.

Ocugen, a biotechnology company, has announced a conference call on August 5, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results. A pre-market earnings announcement will also be issued on that day. Investors can participate via dial-in or webcast. The company is focused on developing novel gene and cell therapies and vaccines, aiming to improve health outcomes globally. Ocugen is advancing a breakthrough therapy platform for retinal diseases and is researching treatments for infectious and orthopedic diseases.

Ocugen announced positive results from a Phase 2/3 pediatric study of COVAXIN™ (BBV152) for COVID-19, demonstrating safety and efficacy in children aged 2-18. The study involved 526 participants who received two doses 28 days apart, showing superior immunogenicity compared to adults. COVAXIN™ is already authorized for emergency use in Mexico for adults, and Ocugen is pursuing pediatric authorization there. The favorable data published in The Lancet Infectious Diseases supports Ocugen’s plans to commercialize COVAXIN™ in North America, catering to demand for traditional vaccines.

Ocugen, a biotechnology company based in Malvern, Pennsylvania, has been recognized by the Philadelphia Business Journal as one of the “2022 Best Places to Work.” This accolade highlights Ocugen's commitment to fostering a positive corporate culture, as determined by employee feedback. Dr. Shankar Musunuri, the CEO, emphasized the importance of this recognition in promoting the company’s mission to innovate health solutions. The awards ceremony for winners in various categories will take place on July 28, 2022.

Ocugen (NASDAQ: OCGN) announced the issuance of U.S. Patent No. 11,351,225 on June 7, 2022, enhancing its gene therapy intellectual property portfolio. This patent covers methods for preventing and treating retinal degenerative diseases, including retinitis pigmentosa and age-related macular degeneration, using specific nuclear hormone receptor genes. The patent, set to expire in March 2034, validates Ocugen's modifier gene therapy platform and strengthens its global patent position.

MALVERN, Pa., June 9, 2022 – Ocugen (NASDAQ: OCGN) announced that Michael Shine, VP of Commercial, will present at the 2022 BIO International Convention in San Diego from June 13-16, 2022. The presentation is set for June 13 at 4:45 p.m. PT, focusing on Ocugen’s clinical pipeline, including its COVID-19 vaccine candidate, COVAXIN™, modifier gene therapy programs, and new cell therapy program, NeoCart®. Ocugen aims to develop innovative therapies to address unmet medical needs and improve global health.

Ocugen, Inc. (NASDAQ: OCGN) announced that its NeoCart^® therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, aiming to expedite development for knee cartilage repair in adults. This innovative cell therapy, a 3D-engineered cartilage product, could potentially prevent osteoarthritis by rebuilding damaged knee cartilage. Developed originally by Histogenics, NeoCart^® represents a significant step in Ocugen's regenerative medicine pipeline as they prepare for Phase 3 clinical trials.

Ocugen announced that Dr. Shankar Musunuri, the company's Chairman and CEO, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 1:30 PM ET in Miami Beach, Florida. The event focuses on the company's innovative gene therapies and vaccines aimed at improving health outcomes. Interested parties can register to watch the chat virtually. A replay will be available on the Investor’s section of the Ocugen website starting on May 24 for 90 days.